Published May 24, 2022
MedPage Today quoted Andrew Talal, MD, MPH, professor of gastroenterology in the Department of Medicine, in a story about a minimally invasive endoscopic procedure associated with resolution of hepatic steatosis and other benefits in patients with nonalcoholic fatty liver disease (NAFLD) and obesity. "A significantly larger number of POSE 2.0 participants had resolution of steatosis, with marked improvements in metabolic parameters," said Talal. "Overall, it appears that POSE 2.0 may be a promising surgical intervention for management of nonalcoholic fatty liver disease in obese individuals." Talal was not involved in the study.